302 related articles for article (PubMed ID: 11499697)
1. Cancer vaccines based on dendritic cells loaded with tumor-associated antigens.
Burdin N; Moingeon P
Cell Biol Toxicol; 2001; 17(2):67-75. PubMed ID: 11499697
[TBL] [Abstract][Full Text] [Related]
2. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
[TBL] [Abstract][Full Text] [Related]
3. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L
J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568
[TBL] [Abstract][Full Text] [Related]
4. Tumor lysate-loaded Bacterial Ghosts as a tool for optimized production of therapeutic dendritic cell-based cancer vaccines.
Dobrovolskienė N; Pašukonienė V; Darinskas A; Kraśko JA; Žilionytė K; Mlynska A; Gudlevičienė Ž; Mišeikytė-Kaubrienė E; Schijns V; Lubitz W; Kudela P; Strioga M
Vaccine; 2018 Jul; 36(29):4171-4180. PubMed ID: 29895501
[TBL] [Abstract][Full Text] [Related]
5. Advances in dendritic cell-based vaccine of cancer.
Zhang X; Gordon JR; Xiang J
Cancer Biother Radiopharm; 2002 Dec; 17(6):601-19. PubMed ID: 12537664
[TBL] [Abstract][Full Text] [Related]
6. Genetically engineered dendritic cell-based cancer vaccines (review).
Bubeník J
Int J Oncol; 2001 Mar; 18(3):475-8. PubMed ID: 11179474
[TBL] [Abstract][Full Text] [Related]
7. Loading DCs with Ag.
Vari F; Hart DN
Cytotherapy; 2004; 6(2):111-21. PubMed ID: 15203987
[TBL] [Abstract][Full Text] [Related]
8. Progress of dendritic cell-based cancer vaccines for patients with hematological malignancies.
Ni M; Hoffmann JM; Schmitt M; Schmitt A
Expert Opin Biol Ther; 2016 Sep; 16(9):1113-23. PubMed ID: 27238400
[TBL] [Abstract][Full Text] [Related]
9. mRNA-based dendritic cell vaccines.
Benteyn D; Heirman C; Bonehill A; Thielemans K; Breckpot K
Expert Rev Vaccines; 2015 Feb; 14(2):161-76. PubMed ID: 25196947
[TBL] [Abstract][Full Text] [Related]
10. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
11. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
Timmerman JM; Levy R
J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
[TBL] [Abstract][Full Text] [Related]
12. Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models.
Zhang R; Yuan F; Shu Y; Tian Y; Zhou B; Yi L; Zhang X; Ding Z; Xu H; Yang L
Cancer Immunol Immunother; 2020 Jan; 69(1):135-145. PubMed ID: 31807878
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses.
Weigel BJ; Panoskaltsis-Mortari A; Diers M; Garcia M; Lees C; Krieg AM; Chen W; Blazar BR
Exp Hematol; 2006 Oct; 34(10):1403-12. PubMed ID: 16982333
[TBL] [Abstract][Full Text] [Related]
14. DC-based cancer vaccines: lessons from clinical trials.
Brody JD; Engleman EG
Cytotherapy; 2004; 6(2):122-7. PubMed ID: 15203988
[No Abstract] [Full Text] [Related]
15. The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells.
Willemen Y; Van den Bergh JM; Bonte SM; Anguille S; Heirman C; Stein BM; Goossens H; Kerre T; Thielemans K; Peeters M; Van Tendeloo VF; Smits EL; Berneman ZN
Oncotarget; 2016 Nov; 7(45):73960-73970. PubMed ID: 27659531
[TBL] [Abstract][Full Text] [Related]
16. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.
Tacken PJ; de Vries IJ; Torensma R; Figdor CG
Nat Rev Immunol; 2007 Oct; 7(10):790-802. PubMed ID: 17853902
[TBL] [Abstract][Full Text] [Related]
17. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination.
Wei FQ; Sun W; Wong TS; Gao W; Wen YH; Wei JW; Wei Y; Wen WP
J Exp Clin Cancer Res; 2016 Jan; 35():18. PubMed ID: 26795730
[TBL] [Abstract][Full Text] [Related]
18. Genetically modified tumour vaccines--where we are today.
Nawrocki S; Mackiewicz A
Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
[TBL] [Abstract][Full Text] [Related]
19. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy via dendritic cells.
Palucka K; Banchereau J
Nat Rev Cancer; 2012 Mar; 12(4):265-77. PubMed ID: 22437871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]